Condition category
Urological and Genital Diseases
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Urinary catheterisation is a procedure used to drain the bladder and collect urine, through a thin, flexible tube called a catheter. It involves the catheter being passed into the bladder via the urethra (the tube through which urine passes) so that the urine in the bladder can be drained into a collecting bag. Some patients require catheters to be in place long-term. Long-term (over 28 days) urinary catheter users are at risk of catheter-associated urinary tract infections (CAUTI). This can mean courses of antibiotics, early removal of the catheter, blockage of the catheter, and other serious complications for patients. This study will look at catheters that have been treated with three types of antimicrobial (killing microorganisms such as bacteria) drugs can prevent bacteria from attaching to the catheter to prevent infection. The aim of this study is to find out whether there are any side-effects associated with use of antimicrobial urinary catheters.

Who can participate?
Patients aged 16 years or over who have previously had a urinary catheter for at least 28 days and need another urinary catheter to be put in place for at least 28 days.

What does the study involve?
When participants are next due to have their long-term urinary catheter put in place, the antimicrobial urinary catheter is inserted (following standard procedures). Participants are then interviewed by telephone after 24, 48 and 72 hours and then weekly until the catheter is removed about their experience with the antimicrobial catheter. The catheter stays in place for the length of time needed for each individual patient. When the catheter is removed, it is sent to the lab so that bacteria levels can be tested. Participants are also interviewed at the end of the study to find out if it would be feasible to conduct a larger study.

What are the possible benefits and risks of participating?
There is no guarantee of direct benefits for those participating, however the catheters used in the study could prevent the development of CAUTI. There are no direct risks of participating other than the general risks involved with having a catheter.

Where is the study run from?
Queen's Medical Centre, Nottingham (UK)

When is the study starting and how long is it expected to run for?
June 2016 to May 2018

Who is funding the study?
National Institute for Health Research (UK)

Who is the main contact?
Miss Katherine Belfield

Trial website

Contact information



Primary contact

Miss Katherine Belfield


Contact details

Department of Academic Orthopaedics
and Sports Medicine
C Floor
West Block
Queen's Medical Centre
Derby Road
United Kingdom
+44 1158 231113

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

A novel antimicrobial urinary catheter for long-term catheter users: a study of its safety


Study hypothesis

The aim of this study is to determine whether the addition of three antimicrobials to a silicone urinary catheter produces any side effects when used in patients.

Ethics approval

East Midlands - Edgbaston Research Ethics Committee, 12/09/2016, ref: 16/WM/0353

Study design

Non-randomised; Interventional; Design type: Prevention, Device

Primary study design


Secondary study design

Non randomised study

Trial setting


Trial type


Patient information sheet

See additional files


Specialty: Renal disorders, Primary sub-specialty: Renal disorders; UKCRC code/ Disease: Renal and Urogenital/ Other disorders of kidney and ureter


Consenting participants will receive the antimicrobial urinary catheter at their next planned catheter insertion, and will be asked to answer questions regarding experience with the antimicrobial catheter via 15 minute telephone interviews at 24 hours, 48 hours, 72 hours and every week after the catheter is inserted.

The participants' involvement will range from 28 days to 84 days depending on their normal catheterisation schedule (i.e. if they have their catheter changed every 6 weeks, the antimicrobial catheter will remain in place for 6 weeks). The participants will also be asked to fill in a questionnaire about their interest and understanding of a future randomised controlled trial which will inform the sample size calculation and feasibility for this future study.

Finally, at the end of the trial when the catheter is removed, it will be collected and analysed in the laboratory for bacterial attachment.

Intervention type



Drug names

Primary outcome measure

Rate of adverse events reported as attributable to the antimicrobial urinary catheter is measured through telephone interviews at 24 hours, 48 hours, 72 hours and every week until catheter removal.

Secondary outcome measures

1. Type of adverse events (if reported) are measured through telephone interviews at 24 hours, 48 hours, 72 hours and every week until catheter removal
2. Time to event (if reported) is measured through telephone interviews at 24 hours, 48 hours, 72 hours and every week until catheter removal
3. Removal of catheter before the end of the trial (if reported) is measured through telephone interviews at 24 hours, 48 hours, 72 hours and every week until catheter removal
4. Overall patient acceptability is measured through telephone interviews at 24 hours, 48 hours, 72 hours and every week until catheter removal
5. Catheter efficacy will be determined by collecting the trial device at the end of the trial, and examining the attached bacteria in the laboratory using standard microbiological culture techniques at study end

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Aged 16 years and over
2. Previously had a urethral urinary catheter for 28 days or more and will require another urethral urinary catheter for 28 days or more
3. Able to response verbally and speak on the telephone about the treatment
4. Able to understand spoken and written English and speak English fluently

Participant type


Age group




Target number of participants

Planned Sample Size: 60; UK Sample Size: 60

Participant exclusion criteria

1. Pregnancy
2. Lacking capacity to provide consent
3. Allergy to Rifampicin, Sparfloxacin (or any other fluoroquinolone antibiotic), Triclosan or Silicone
4. History of uncontrolled/unmanageable autonomic dysreflexia
5. Significantly impaired bladder and urethral sensation

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Queen's Medical Centre
Nottingham University Hospitals NHS Trust Derby Road
United Kingdom

Sponsor information


University of Nottingham

Sponsor details

and Graduate Services
Kings Meadow Campus
Lenton Lane
United Kingdom
+44 1158 467906

Sponsor type




Funder type


Funder name

National Institute for Health Research

Alternative name(s)


Funding Body Type

government organisation

Funding Body Subtype

Federal/National Government


United Kingdom

Results and Publications

Publication and dissemination plan

Results will be published in a relevant journal and lay materials will be distributed to trial participants at the end of the trial.

IPD sharing statement:
The datasets generated during and/or analysed during the current study will be available upon request from Miss Katherine Belfield at

Intention to publish date


Participant level data

Available on request

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

13/11/2017: The ISRCTN prospective/retrospective flag compares the date of registration with the recruitment start date and does not include any grace period. The registration of this study was requested through the NIHR Portfolio and was finalised within 6 months of the recruitment starting.